INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA–RELATED CYSTOID MACULAR EDEMA
INTRAVITREAL DEXAMETHASONE IMPLANT IN RETINITIS PIGMENTOSA–RELATED CYSTOID MACULAR EDEMA
复制标题
玻璃体腔内植入地塞米松治疗色素性视网膜炎相关黄斑囊样水肿
DOI：
--
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
A. Teixeira
中科院分区：
文献类型：
--
作者：
A. Mansour;Huda A. Sheheitli;C. Kucukerdonmez;Robert A. Sisk;Raphael Moura;M. Moschos;L. H. Lima;L. Al;J. Arevalo;M. Maia;R. Foster;O. Kayikcioglu;I. Kozák;S. Kurup;H. Zegarra;R. Gallego;R. Hamam;R. Bejjani;E. Çınar;E. T. Erakgün;A. Kimura;A. Teixeira
目的：报告玻璃体腔内植入地塞米松治疗视网膜色素变性和黄斑囊样水肿的临床效果。研究方法：接受玻璃体内地塞米松植入的视网膜色素变性和黄斑囊样水肿患眼的多中心回顾性病例系列。主要结果指标为LogMAR的最佳矫正视力和中心黄斑厚度。统计分析采用双尾比较和Wilcoxon符号秩检验。结果：34例患者共45只眼，平均年龄32.7岁（范围16-57），平均随访15.5 ± 13.0个月。首次注射后3个月，平均初始最佳矫正视力从0.61 ± 0.38（20/81）提高到0.37 ± 0.16（20/47）（P = 0.012），而平均黄斑中心厚度（m）从506 ± 288 m降低到311.7 ± 71.6 m（P < 0.001），平均眼内压从15.7 ± 2.3 mmHg升高到19.8 ± 11.0 mmHg（P = 0.01）。14只眼睛进行了多次注射（1-7次再注射），平均间隔为6个月。多次注射的治疗效果是持久的，但有七只眼睛出现了视觉上显著的白内障。结论：大约一半的眼睛的最佳矫正视力提高了4个月。受益最大的是人工晶状体眼，类固醇无反应，初始黄斑中心厚度较大，荧光素染料大量渗漏。
Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16–57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (&mgr;m) decreased from 506 ± 288 &mgr;m to 311.7 ± 71.6 &mgr;m (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1–7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage.
影响因子：
2.2
作者：
G. Adamus;Shaomei Wang;Madison H. Kyger;A. Worley;B. Lu;G. Burrows
通讯作者：
G. Adamus;Shaomei Wang;Madison H. Kyger;A. Worley;B. Lu;G. Burrows